U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   Form 10QSB

                   Quarterly Report Under Section 13 or 15 (d)
                     of the Securities Exchange Act of 1934

                  For the Quarterly Period Ended March 31, 2003

                           Commission File No. 0-12968

                        INMEDICA DEVELOPMENT CORPORATION
                        --------------------------------
       (Exact name of small business issuer as specified in its charter)



             Utah                                   87-0397815
-------------------------------                   ----------------
(State or other jurisdiction of                   (I.R.S. Employer
 incorporation of organization)                   Identification Number)

                         825 North 300 West, Suite N132
                           Salt Lake City, Utah 84103
                           --------------------------
                    (Address of principal executive offices)

                         Registrant's telephone number:
                                 (801) 521-9300
                         ------------------------------

Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act of 1934 during the past 12 months (or for such
shorter period that the  registrant was required to file such reports),  and (2)
has been subject to such filing requirements for the past 90 days: Yes [X] No[ ]

The number of shares outstanding of the registrant's only class of common stock,
par value $.001 per share, as of May 1, 2003 was 15,982,993 shares.

                                       1
<PAGE>

PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements

                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                           CONSOLIDATED BALANCE SHEET

                                      ASSETS
                                     ------
                                               As of
                                             March 31,
                                              2003
                                           (Unaudited)
                                           -----------

        CURRENT ASSETS:
           Cash                             $   39,478
           Securities available for sale             1
           Prepaid expenses and other              825

                                            ----------
                Total current assets            40,304


        EQUIPMENT AND FURNITURE,
          at cost, less accumulated
          depreciation of $253,167                 708

                                            ----------


                Total assets                $   41,012
                                            ==========














            See notes to consolidated financial statements

                                       2

<PAGE>


                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                     CONSOLIDATED BALANCE SHEET (Continued)

                      LIABILITIES AND STOCKHOLDERS' EQUITY
                      -------------------------------------

                                                          As of
                                                         March 31,
                                                           2003
                                                          ------
                                                       (Unaudited)

        CURRENT LIABILITIES:
           Related party consulting fees payable       $    48,000
           Accounts payable                                  1,000
           Preferred stock dividend payable                 13,240
                                                      ------------

                Total current liabilities                   62,240
                                                       -----------

            MINORITY INTEREST                              124,208
                                                       -----------

        STOCKHOLDERS' EQUITY:
           Preferred stock, 10,000,000
            shares authorized; Series A
            preferred stock, cumulative and
            convertible, $4.50 par value,
            1,000,000 shares designated,
            21,016 shares issued and
            outstanding                                     94,573
           Common stock, $.001 par value;
            40,000,000 shares authorized,
            15,982,993 issued and outstanding               15,983
           Additional paid-in capital                    8,024,260
           Accumulated deficit                          (8,280,252)
                                                        ----------

                Total stockholders' equity                (145,436)
                                                        ----------
                Total liabilities and
                 stockholders' equity                   $  41,012
                                                        ==========











            See notes to consolidated financial statements

                                       3
<PAGE>



                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF OPERATIONS

                                               For the Three
                                               Months Ended
                                                 March 31,
                                             2003        2002
                                           --------    --------
                                                (Unaudited)
          TOTAL ROYALTY REVENUES            $   -0-         -0-
                                           --------    --------

          OPERATING EXPENSES:
            General and
              administrative                 62,097      91,928
            Research and
             development                      1,841       2,869
                                           --------    --------
              Total operating expenses       63,938      94,797
                                           --------    --------

          LOSS FROM OPERATIONS              (63,938)    (94,797)
                                           --------    --------

          OTHER INCOME (EXPENSE):
            Other income, net                    20          39
            Interest expense                    -0-        (241)
                                           --------    --------
             Total other expense, net            20        (202)
                                           --------    --------

          LOSS BEFORE MINORITY INTEREST     (63,918)    (94,999)

           MINORITY INTEREST                  9,600      10,415
                                           --------    --------
          NET LOSS                          (54,318)    (84,584)

          PREFERRED STOCK DIVIDENDS          (1,891)     (1,891)
                                           --------    --------

          NET LOSS APPLICABLE TO
           COMMON STOCKHOLDERS             $(56,209) $ (86,475)
                                           ========   ========
          NET LOSS PER COMMON SHARE
            (BASIC AND DILUTED)            $   (.00)  $   (.01)
                                           ========   ========

          Weighted average number
           of common shares outstanding   15,982,993 15,982,993
                                           =========  =========



            See notes to consolidated financial statements.

                                       4
<PAGE>


                 INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                      CONSOLIDATED STATEMENTS OF CASH FLOWS


                                                    For the Three
                                                    Months Ended
                                                      March 31,
                                                    2003       2002
                                                  --------   --------
                                                     (Unaudited)
     CASH FLOWS FROM OPERATING ACTIVITIES:

       Net loss                                  $ (54,318) $( 84,584)
       Adjustments to reconcile net
         loss to net cash used in
         operating activities-
           Depreciation and amortization                44        -0-
           Minority interest in losses              (9,600)   (10,415)
           Change in assets and liabilities
             Prepaid expenses and other                625      5,623
             Consulting fee payable to
               related party                         6,000      6,000
               Note payable                            -0-     (6,000)
             Accounts payable                         (704)    (2,619)
             Accrued payroll                           -0-     (3,500)
                                                  --------   --------
                Net cash used in
                  operating activities             (57,953)   (95,495)
                                                  --------   --------

     CASH FLOWS USED IN INVESTING ACTIVITES:
       Purchase of equipment and furniture             -0-       (884)
                                                  --------   --------
                       Net cash used in investing
                         activities                    -0-       (884)
                                                 ---------  ---------

     CASH FLOWS FROM FINANCING ACTIVITIES:
       Preferred stock dividend                        -0-     (3,783)

                                                  -------- -------
                Net cash used in financing
                  activities                           -0-     (3,783)
                                                  ---------- --------








           See notes to consolidated financial statements.

                                       5
<PAGE>



                INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
                CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)

                                                   For the Three
                                                   Months Ended
                                                     March 31,
                                                   2003     2002
                                                ---------- -------
                                                    (Unaudited)


   NET DECREASE IN CASH                          (57,953)    (100,162)

   CASH AT BEGINNING OF PERIOD                    97,431      106,739
                                                 -------     --------

   CASH AT END OF PERIOD                        $ 39,478      $ 6,577
                                                 =======      =======

























          See notes to consolidated financial statements.

                                       6
<PAGE>




INMEDICA DEVELOPMENT CORPORATION AND SUBSIDIARY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. Basis of Presentation
The  accompanying   unaudited  consolidated  financial  statements  of  InMedica
Development  Corporation and its majority owned subsidiary,  MicroCor, Inc. (the
"Company")  have been prepared on a going concern basis which  contemplates  the
realization of assets and  satisfaction  of liabilities  that might be necessary
should  the  Company  be unable to  continue  as a going  concern.  The  Company
generated  net losses of $54,318 and $84,584 for the three month  periods  ended
March 31, 2003 and 2002,  respectively,  and negative cash flows from operations
of $57,953  and $95,495  for the three  month  periods  ended March 31, 2003 and
2002, respectively. As of March 31, 2003, the Company had an accumulated deficit
of  $8,280,252.  At March 31,  2003,  the  Company  had a  stockholders'  equity
(deficit) of $(145,436).  These  conditions  raise  substantial  doubt as to the
Company's  ability to  continue  as a going  concern.  The  Company's  continued
existence is  dependent  upon its ability to execute its  operating  plan and to
obtain additional debt or equity  financing.  There can be no assurance that the
necessary debt or equity  financing  will be available,  or will be available on
terms acceptable to the Company.  Management's  operating plan includes pursuing
additional  strategic  alliances  and  licensing  agreements,  and if warranted,
preparation  for the clinical  trials that will be required for FDA approval for
the medical products that are currently under  development,  pursuant to the Chi
Lin development agreement, utilizing the Non-invasive Hematocrit Technology.

The accompanying consolidated financial statements of the Company are unaudited.
However,  in management's  opinion,  all adjustments,  consisting only of normal
recurring adjustments necessary for fair presentation of results for the interim
periods shown,  have been made.  Results for interim periods are not necessarily
indicative  of  those  to be  expected  for the full  year.  These  consolidated
financial statements should be read in conjunction with the audited consolidated
financial statements and notes to consolidated  financial statements included in
the Company's annual report on form 10-KSB for the year ended December 31, 2002.

2_       Summary of Significant Accounting Policies

        Principles of  Consolidation  - The  consolidated  financial  statements
        include  the   accounts  of  InMedica   and   MircoCor.   All   material
        inter-company accounts and transactions have been eliminated.

        Use of Estimates - The preparation of financial statements in conformity
        with accounting  principles  generally  accepted in the United States of
        America  requires  management  to make  estimates and  assumptions  that
        affect the reported  amounts of assets and liabilities and disclosure of
        contingent   assets  and  liabilities  at  the  date  of  the  financial
        statements and the reported  amounts of revenues and expenses during the
        reporting period. Actual results could differ from those estimates.


                                       7
<PAGE>


Item 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

LIQUIDITY AND CAPITAL  RESOURCES.  During the three  months ended March 31, 2003
        liquidity resulted from the sale of stock by InMedica and its subsidiary
        MicroCor pursuant to the Stock Purchase Agreement dated May 10, 2001. As
        of March 31, 2003  InMedica and MicroCor had each  received  payments of
        $500,000 from Chi Lin and Chi Lin's stock  purchase  obligation  has now
        been satisfied.

The     funds  generated  from the sale of stock in 2001 were the sole source of
        the  Company's  cash  flow  and are  sufficient  to meet  the  Company's
        operating  expenses only through June 30, 2003. While the Company has in
        the past  borrowed  from  affiliates,  any  borrowing in the future from
        affiliates,  if  available,  is not expected to be sufficient to provide
        future liquidity needs,  retire  obligations and fund continued research
        and development.

RESULTS OF  OPERATIONS.  InMedica  incurred  net losses  during the three  month
        period  ended  March 31, 2003 and 2002.  The Company had an  accumulated
        deficit of $8,280,252 as of March 31, 2003. No revenues from  operations
        are  expected  in the  foreseeable  future.  The net loss for the period
        ended March 31, 2003  decreased  to $54,318  compared to the net loss of
        $84,584  for  2002,  primarily  due to an  decrease  in total  operating
        expenses of $30,859. The decrease in operating expenses is the result of
        reduced insurance costs, accounting and legal fees.

Item 3:   Controls and Procedures

         The Company's Chief Executive  Officer and Chief Financial Officer have
         concluded, based on an evaluation conducted within 90 days prior to the
         filing date of this Quarterly  Report on Form 10-QSB that the Company's
         disclosure  controls and  procedures  (as defined in Exchange Act Rules
         13a - 14(c)  and 15d -  14(c))  have  functioned  effectively  so as to
         provide those officers the information  necessary to evaluate  whether:
         (i) this Quarterly  Report on Form 10-QSB contains any untrue statement
         of a material fact or omits to state a material fact  necessary to make
         the  statements  made, in light of the  circumstances  under which such
         statements  were  made,  not  misleading,  with  respect  to the period
         covered by this Quarterly Report on Form 10-QSB, and (ii) the financial
         statements,  and other financial information included in this Quarterly
         Report on Form  10-QSB,  fairly  present in all  material  respects the
         financial  condition,  results  of  operations  and  cash  flows of the
         Company as of, and for, the periods presented therein.  There have been
         no significant  changes in the Company's  internal controls or in other
         factors that could significantly affect internal controls subsequent to
         the  evaluation  date,  nor any  significant  deficiencies  or material
         weaknesses in such controls requiring  corrective actions. As a result,
         no corrective actions were required or taken.


                                       8
<PAGE>


     PART II - OTHER INFORMATION

Item 1.    Legal Proceedings:
           None

Item 2.    Changes in Securities:
           None

Item 3.    Defaults Upon Senior Securities:
           None

Item 4.    Submission of Matters to a Vote of Security Holders:
           None

Item 5.    Other Information:
           None

Item 6.    Exhibits and Reports on Form 8-K:
               None






                                       9

<PAGE>



                                   SIGNATURES

         In accordance with the requirements of the Exchange Act, the registrant
caused  this  report to be signed on its behalf by the  undersigned,  there-unto
duly authorized.

                            INMEDICA DEVELOPMENT CORPORATION
Dated: May 1, 2003
--------------------
                                By /s/ Ralph Henson
                                -------------------
                                Ralph Henson, CEO


                                By /s/ Richard Bruggeman
                                ------------------------
                                Richard Bruggeman, Treasurer




























                                       10



<PAGE>

                      CERTIFICATION PURSUANT TO SECTION 302
                        OF THE SARBANES-OXLEY ACT OF 2002

        I, Ralph Henson,certify that:

        1. I have  reviewed  this  quarterly  report on Form  10-QSB of InMedica
        Development Corporation.

        2. Based on my  knowledge,  this  quarterly  report does not contain any
        untrue  statement  of a material  fact or omit to state a material  fact
        necessary to make the  statements  made,  in light of the  circumstances
        under which such  statements  were made, not misleading  with respect to
        the period covered by this quarterly report.

        3. Based on my knowledge, the financial statements,  and other financial
        information  included in this  quarterly  report,  fairly present in all
        material  respects the financial  condition,  results of operations  and
        cash flows of the  registrant  as of, and for, the periods  presented in
        this quarterly report.

         4. The registrant's other certifying officers and I are responsible for
        establishing  and  maintaining  disclosure  controls and  procedures (as
        defined in Exchange Act Rules 13a-14 and 15d-14) for the  registrant and
        have:

         a) designed  such  disclosure  controls and  procedures  to ensure that
        material   information   relating  to  the  registrant,   including  its
        consolidated  subsidiaries,  is made known to us by others  within those
        entities,  particularly during the period in which this quarterly report
        is being prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
        and  procedures  as of a date within 90 days prior to the filing date of
        this quarterly report (the Evaluation Date); and

            c)  presented in this  quarterly  report our  conclusions  about the
        effectiveness  of the disclosure  controls and  procedures  based on our
        evaluation as of the Evaluation Date;


                                       11
<PAGE>


     5. The registrant's other certifying  officers and I have disclosed,  based
        on our most recent  evaluation,  to the  registrant's  auditors  and the
        audit  committee  of   registrant's   board  of  directors  (or  persons
        performing the equivalent functions):

          a) all significant deficiencies in the design or operation of internal
        controls  which  could  adversely  affect  the  registrant's  ability to
        record, process, summarize and report financial data and have identified
        for the  registrant's  auditors  any  material  weaknesses  in  internal
        controls; and

             b) any fraud, whether or not material,  that involves management or
        other employees who have a significant role in the registrant's internal
        controls.

     6. The registrant's other certifying  officers and I have indicated in this
        quarterly  report  whether  or not there  were  significant  changes  in
        internal  controls or in other factors that could  significantly  affect
        internal controls  subsequent to the date of our most recent evaluation,
        including any corrective actions with regard to significant deficiencies
        and material weaknesses.

DATE: May 1, 2003


/s/ Ralph Henson_______
Ralph Henson, President


                                       12
<PAGE>



                      CERTIFICATION PURSUANT TO SECTION 302
                        OF THE SARBANES-OXLEY ACT OF 2002

        I, Richard Bruggeman, certify that:

        1. I have  reviewed  this  quarterly  report on Form  10-QSB of InMedica
        Development Corporation.

        2. Based on my  knowledge,  this  quarterly  report does not contain any
        untrue  statement  of a material  fact or omit to state a material  fact
        necessary to make the  statements  made,  in light of the  circumstances
        under which such  statements  were made, not misleading  with respect to
        the period covered by this quarterly report.

        3. Based on my knowledge, the financial statements,  and other financial
        information  included in this  quarterly  report,  fairly present in all
        material  respects the financial  condition,  results of operations  and
        cash flows of the  registrant  as of, and for, the periods  presented in
        this quarterly report.

         4. The registrant's other certifying officers and I are responsible for
        establishing  and  maintaining  disclosure  controls and  procedures (as
        defined in Exchange Act Rules 13a-14 and 15d-14) for the  registrant and
        have:

         a) designed  such  disclosure  controls and  procedures  to ensure that
        material   information   relating  to  the  registrant,   including  its
        consolidated  subsidiaries,  is made known to us by others  within those
        entities,  particularly during the period in which this quarterly report
        is being prepared;

          b) evaluated the effectiveness of the registrant's disclosure controls
        and  procedures  as of a date within 90 days prior to the filing date of
        this quarterly report (the Evaluation Date); and

          c)  presented  in this  quarterly  report  our  conclusions  about the
        effectiveness  of the disclosure  controls and  procedures  based on our
        evaluation as of the Evaluation Date;

     5. The registrant's other certifying  officers and I have disclosed,  based
        on our most recent  evaluation,  to the  registrant's  auditors  and the
        audit  committee  of   registrant's   board  of  directors  (or  persons
        performing the equivalent functions):

                                       13
<PAGE>


          a) all significant deficiencies in the design or operation of internal
        controls  which  could  adversely  affect  the  registrant's  ability to
        record, process, summarize and report financial data and have identified
        for the  registrant's  auditors  any  material  weaknesses  in  internal
        controls; and

          b) any fraud,  whether or not material,  that  involves  management or
        other employees who have a significant role in the registrant's internal
        controls.

     6. The registrant's other certifying  officers and I have indicated in this
        quarterly  report  whether  or not there  were  significant  changes  in
        internal  controls or in other factors that could  significantly  affect
        internal controls  subsequent to the date of our most recent evaluation,
        including any corrective actions with regard to significant deficiencies
        and material weaknesses.

DATE: May 1, 2003


/s/ Richard Bruggeman____
Richard Bruggeman,
 Chief Financial Officer

                                       14
<PAGE>


        EXHIBIT INDEX - INMEDICA DEVELOPMENT CORPORATION
                   FORM 10QSB - SEPTEMBER 30, 2002

EXHIBIT NUMBER             DESCRIPTION
      99               Sarbanes-Oxley Section 906                  Certification



                                       15
<PAGE>



                 CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350
                       AS ADOPTED PURSUANT TO SECTION 906
                        OF THE SARBANES-OXLEY ACT OF 2002

Each of the  undersigned  hereby  certifies  in his  capacity  as an  officer of
InMedica Development  Corporation (the Company) that the Quarterly Report of the
Company on Form 10QSB for the period  ended March 31, 2003 fully  complies  with
the  requirements  of Section 13(a) of the  Securities  Exchange Act of 1934 and
that the information  contained in such report fairly presents,  in all material
respects,  the financial condition of the Company at the end of such periods and
the results of operations of the Company for such periods.


/s/ Ralph Henson
 Ralph Henson, Chief Executive Officer

/s/ Richard Bruggeman
Richard Bruggeman, Chief Financial Officer




                                       16